Influence of cancer cachexia on drug liver metabolism and renal elimination in rats

Journal of Cachexia, Sarcopenia and Muscle

Volumn , Issue , 2015, Pages 45-52

  Cvan Trobec, Katja ^a   Kerec Kos, Mojca ^a   Trontelj, Jurij ^a   Grabnar, Iztok ^a   Tschirner, Anika ^b   Palus, Sandra ^c   Anker, Stefan D ^b,c   Springer, Jochen ^c   Lainscak, Mitja ^a,d  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d General Hospital Celje   (Slovenia)

Author keywords

Cachexia; Cancer; Drug metabolism; Liver metabolism; Pharmacokinetic; Renal function

Indexed keywords

CYTOCHROME P450 2D6; IOHEXOL; MIDAZOLAM; PROPRANOLOL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG METABOLISM; GLOMERULUS FILTRATION RATE; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION; VOLUME OF DISTRIBUTION;

EID: 84975144513     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12012     Document Type: Article

References (33)

1. Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle 2013; 4: 173–179.
2. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10: 90–99.
3. Jacques KA, Erstad BL. Availability of information for dosing injectable medications in underweight or obese patients. Am J Health Syst Pharm 2010; 67: 1948–1950.
4. Trobec K, Kerec Kos M, von Haehling S, Springer J, Anker SD, Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One 2013; 8: e79603.
5. Barry RE. Malignancy, weight loss, and the small intestinal mucosa. Gut 1974; 15: 562–570.
6. Sandek A, Valentova M, von Haehling S, Doehner W, Anker SD. The small intestine: a critical linkage in pathophysiology of cardiac cachexia. Int J Cardiol 2011; 146:277–278.
7. Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM, Schols A, Sieber CC. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 2010; 29: 154–159.
8. Rogers JF, Rocci ML, Haughey DB, Bertino JS. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. ClinPharmacol Ther 2003; 73: 153–158.
9. Pirttiaho HI, Sotaniemi EA, Pelkonen RO, Pitkänen U, Anttila M, Sundqvist H. Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol. Br J Clin Pharmacol 1980; 9: 399–405.
10. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995; 6: 257–263.
11. Springer J, Tschirner A, Hartman K, Palus S, Wirth EK, Ruis SB, Möller N, von Haehling S, Argiles JM, Köhrle J, Adams V, Anker SD, Doehner W. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int J Cancer 2012; 131: 2187-2196.
12. Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, Kaschina E, Palus S, Pötsch M, von Websky K, Hocher B, Latouche C, Jaisser F, Morawietz L, Coats AJ, Beadle J, Argiles JM, Thum T, Földes G, Doehner W, Hilfiker-Kleiner D, Force T, Anker SD. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 2014; 35: 932-941.
13. Cvan Trobec K, Trontelj J, Springer J, Lainscak M, Kerec Kos M. Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of bisoprolol, ramiprilat, propranolol and midazolam in rat dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 958C: 29-35.
14. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Informa Healthcare; 2007.
15. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21: 735–750.
16. Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos 2013; 34: 141–154.
17. Deboer MD. Animal models of anorexia and cachexia. Expert Opin Drug Discov 2009; 4: 1145–1155.
18. Iwamoto K, Watanabe J, Araki K, Deguchi N, Sugiyama H. Effect of age on the hepatic clearance of propranolol in rats. J Pharm Pharmacol 1985; 37: 466–470.
19. Qi JW, Nakamura K, Hosokawa S, Okada Y, Horiuchi R, Yamamoto K. Time-dependent induction of midazolam-1-hydroxylation enzymes in rats treated with St. John's wort. Biol Pharm Bull 2005; 28: 1467–1471.
20. Paixão P, Gouveia LF, Morais JAG. Prediction of drug distribution within blood. Eur J Pharm Sci 2009; 36: 544–554.
21. De Boer T, Wieling J, Meulman E, Reuvers M, Renkema G, den Daas I, van Iersel T, Wemer J, Chen L. Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed Chromatogr 2011; 25:1112–1123.
22. Baker SD, van Schaik RHN, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004; 10: 8341–8350.
23. Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 2002; 87: 277–280.
24. Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res 2006; 12: 7492–7497.
25. Kato R, Takanaka A, Takahashi A, Onoda K. Drug metabolism in tumor-bearing rats. I. Activities of NADPH-linked electron transport and drug-metabolizing enzyme systems in liver microsomes of tumor-bearing rats. Jpn J Pharmacol. 1968; 18: 224–244.
26. Shand DG, Kornhauser DM, Wilkinson GR. Effects of route of administration and blood flow on hepatic drug elimination. J Pharmacol Exp Ther 1975; 195: 424–432.
27. Van Leeuwen PA, Bading JR, Vydelingum NA, Younes RN, de Rooij P, Brennan MF. Organ blood flow in Fischer-344 rats bearing MCA-induced sarcoma. J Appl Physiol (1985) 1991; 71: 1674–1678.
28. Coelho I, Casare F, Pequito DCT, Borghetti G, Yamazaki RK, Brito GAP, Kryczyk M, Fernandes LC, Coimbra TM, Fernandez R. Fish oil supplementation reduces cachexia and tumor growth while improving renal function in tumor-bearing rats. Lipids 2012; 47: 1031–1041.
29. Fernandez R, Piechnik J, Fabris R, Malnic G, Fernandes LC. Effect of chronic fish oil supplementation on renal function of normal and cachectic rats. Braz J Med Biol Res 2004; 37: 1481–1489.
30. Rettori O, Vieira-Matos AN, Gontijo JA. Re-assessment of the renal hydrosaline dysfunction in rats bearing the Walker-256 tumor. Ren Fail 2000; 22: 769–784.
31. Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care 2013; 7: 383–389.
32. Von Haehling S, Lainscak M, Kung T, Cramer L, Fülster S, Pelzer U, Hildebrandt B, Sandek A, Schefold JC, Rauchhaus M, Doehner W, Anker SD. Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. Arch Med Sci 2013; 9: 261–267.
33. Hillon P, Blanchet L, Lebrec D. Effect of propranolol on hepatic blood flow in normal and portal hypertensive rats. Clin Sci (Lond) 1982; 63: 29–32.